Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,712.00
Bid: 2,050.00
Ask: 2,720.00
Change: 0.00 (0.00%)
Spread: 670.00 (32.683%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2,712.00
CCH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Covid-19 update and actions

27 Mar 2020 07:00

RNS Number : 8413H
Coca-Cola HBC AG
27 March 2020
 

Coca-Cola HBC AG

Covid-19 update and actions

 

Zug, Switzerland - 27 March 2020 - On 19 March 2020, in connection with the release of our 2019 Annual Report and full year 2019 audited results announcement, Coca-Cola HBC acknowledged the COVID-19 outbreak and its potential greater impact in people's life, communities and global economy.

 

The COVID-19 global pandemic is an unprecedented event that will in some way touch everybody on the planet. As a food and beverage business, we have a recognised and important role to play in this crisis. The safety of our employees, customers, partners, consumers and products remains our highest priority. Wherever and whenever we can, we are actively supporting those who continue to have their lives changed or impacted by the virus, and those who are tirelessly and selflessly supporting the affected. We remain incredibly grateful for the extraordinary efforts that all our people are making in ensuring business continuity and continued product supply to our customers.

In parallel, we have implemented appropriate contingency and business continuity plans in order to safeguard that our production plants and supply chain remain fully operational. We have implemented global best-practice precautionary and hygiene measures at all our locations, including even stricter sanitation protocols, social distancing, travel restrictions and, where possible, our people are working from home. To-date this has meant that our supply chain is operational. As we move forward and governments step up their efforts to control the spread of COVID-19 we may see some disruption, although the extent and duration is unknown.

 

Current trading

 

Trading in January and February was in line with our expectations. During March, trading across our markets has been dependant on the severity of restrictions on mobility. In markets with heavy restrictions, such as Italy as well as central and southern Europe, demand in the 'out of home' channel has been severely affected. In these markets, 'out of home' represents c. 35-40% of sales.

 

Given this situation, we are already looking at cost-saving measures and reassessing marketing and capex investments. These actions will help to support our profitability.

 

It is still too early to quantify the impact that the COVID-19 pandemic will have on our full year 2020 results. Given the uncertainty of the duration and economic impact of this global pandemic, we no longer believe that it is prudent to provide guidance for the current financial year.

 

 

 

 

Balance sheet and liquidity

 

We benefit from a very strong balance sheet and have adequate liquidity for working capital and investment needs. As of the end of 2019, our net debt to EBITDA ratio was 1.54x. None of our debt facilities are subject to any financial covenants that would impact the Group's liquidity or access to capital. Therefore, as things stand, it remains the Board's intention to propose an ordinary dividend of €0.62 per share to our shareholders in the June 2020 Annual General Meeting.

 

Our strong balance sheet and liquidity position, our leading market shares and largely variable cost base, together with our unique portfolio of brands and resilient and talented people will allow us to weather this unprecedented crisis. When we emerge, we will be able to focus on capturing the many opportunities that we have in front of us. In the meantime, we continue to monitor the COVID-19 pandemic and its impact on our business and will provide further updates as necessary.

 

 

 

Enquiries

Coca‑Cola HBC Group

Investors and Analysts:

Joanna Kennedy

Investor Relations Director

Tel: +44 20 37 444 230

 joanna.kennedy@cchellenic.com

Carla Fabiano

Investor Relations Manager

Tel: +44 20 37 444 231

carla.fabiano@cchellenic.com

Media:

 

David Hart

Group External Communication Director

Tel: +41 41 726 0143

 david.hart@cchellenic.com

 

International media contact:

Teneo

Rob Morgan

Tom Davies

Tel: +44 7557 413 275

robert.morgan@teneo.com

tom.davies@teneo.com

 

 

Greek media contact:

V+O Communications

Argyro Oikonomou

Tel: +30 211 7501219

ao@vando.gr

 

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a leading bottler of The Coca-Cola Company with an annual revenue in excess of €7 billion. It has a broad geographic footprint with operations in 28 countries serving a population of more than 600 million people. Coca-Cola HBC offers a diverse range of primarily non-alcoholic ready-to-drink beverages in the sparkling, juice, water, sport, energy, plant-based beverages and ready-to-drink tea and coffee categories. Coca-Cola HBC is committed to promoting sustainable development in order to create value for its business and for society. This includes providing products that meet the beverage needs of consumers, fostering an open and inclusive work environment, conducting its business in ways that protect and preserve the environment and contribute to the socio-economic development of the local communities. Coca-Cola HBC is ranked among the top sustainability performers in ESG benchmarks such as the Dow Jones Sustainability Indices, CDP, MSCI ESG and FTSE4Good, among others.

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE: CCH) and its shares are listed on the Athens Exchange (ATHEX: EEE). For more information, please visit http://www.coca-colahellenic.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDFIFERVSIDFII
Date   Source Headline
8th May 20245:50 pmRNSTransaction in Own Shares
7th May 20245:29 pmRNSTransaction in Own Shares
3rd May 20245:25 pmRNSTransaction in Own Shares
3rd May 202412:46 pmRNSDirector/PDMR Shareholding
3rd May 202412:38 pmRNSDirector/PDMR Shareholding
2nd May 20245:41 pmRNSTransaction in Own Shares
2nd May 202412:40 pmRNSAthens Exchange trading date of ordinary shares
1st May 20245:47 pmRNSTransaction in Own Shares
1st May 202410:09 amRNSBlock listing Interim Review
1st May 20249:10 amRNSIssue of equity and total voting rights
30th Apr 20247:00 amRNSStrong start; reiterating 2024 guidance
19th Apr 20249:20 amRNSNotice of AGM
18th Apr 20244:21 pmRNSDirector/PDMR Shareholding
5th Apr 20242:17 pmRNSNotice of Results
2nd Apr 202411:12 amRNSIssue of equity and total voting rights
28th Mar 20245:55 pmRNSDirector/PDMR Shareholding
28th Mar 20245:47 pmRNSDirector/PDMR Shareholding
28th Mar 20245:42 pmRNSDirector/PDMR Shareholding
28th Mar 20245:26 pmRNSTransaction in Own Shares
27th Mar 20245:23 pmRNSTransaction in Own Shares
26th Mar 20245:05 pmRNSTransaction in Own Shares
26th Mar 20249:09 amRNSDirector/PDMR Shareholding
25th Mar 20245:10 pmRNSTransaction in Own Shares
22nd Mar 20245:27 pmRNSTransaction in Own Shares - Replacement
22nd Mar 20245:05 pmRNSTransaction in Own Shares
21st Mar 20245:40 pmRNSTransaction in Own Shares
20th Mar 20245:33 pmRNSTransaction in Own Shares
19th Mar 20245:20 pmRNSTransaction in Own Shares
19th Mar 20241:19 pmRNSDirector/PDMR Shareholding
18th Mar 20245:20 pmRNSTransaction in Own Shares
15th Mar 20246:25 pmRNSTransaction in Own Shares
15th Mar 20245:58 pmRNSAnnual Financial Report
14th Mar 20245:30 pmRNSTransaction in Own Shares
14th Mar 20243:04 pmRNSDirector/PDMR Shareholding
14th Mar 20242:56 pmRNSDirector/PDMR Shareholding
13th Mar 20245:20 pmRNSTransaction in Own Shares
12th Mar 20245:15 pmRNSTransaction in Own Shares
11th Mar 20245:50 pmRNSTransaction in Own Shares
8th Mar 20245:45 pmRNSTransaction in Own Shares
7th Mar 20245:20 pmRNSTransaction in Own Shares
6th Mar 20245:10 pmRNSTransaction in Own Shares
5th Mar 20245:15 pmRNSTransaction in Own Shares
4th Mar 20245:55 pmRNSTransaction in Own Shares
1st Mar 20245:15 pmRNSTransaction in Own Shares
1st Mar 20249:25 amRNSIssue of Equity and total voting rights
29th Feb 20245:25 pmRNSTransaction in Own Shares
29th Feb 20243:10 pmRNSDirector/PDMR Shareholding
29th Feb 20243:00 pmRNSDirector/PDMR Shareholding
29th Feb 20242:53 pmRNSDirector/PDMR Shareholding
28th Feb 20245:25 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.